Putrino Lab

Trying out a new caffeine delivery system today (pouches) so everyone pray for my team as I become “more productive”…folks with #LongCOVID, #MECFS and other infection-associated chronic illnesses who can tolerate caffeine for energy: have you tried pouches? Any feedback? 👀

YouTube video by Julia Claire Taylor “Finding our Voices after COVID” written by Emma Smith, journalist

Watch it here: Finding Our Voices After COVID

Julia Claire Taylor is an opera singer based in NYC who lost her ability to perform after a COVID infection in 2022. A clinical trial with @putrinolab.bsky.social allowed her to reach a milestone this October. www.youtube.com/watch?v=SJZM...
#LongCOVID

Time to get this #LongCOVID trial utilizing @invivyd.bsky.social’s newest monoclonal, VYD-2311 out ASAP. I called on @NIH RECOVER-TLC to take this seriously last year and we have seen no movement on this obvious and innovative target. This can’t wait any longer.
investors.invivyd.com/news-release...

drive a path forward to FDA approval for folks with Long COVID to access the therapy. Huge thanks to my incredible team for driving this work forward and to Dr Skip Pridgen and Brian Corday who have been working day and night toward helping us get this to pwLC faster.

/end

announce that we have received an IND-exemption from the FDA to begin the larger, placebo-controlled trial of this regimen. This will allow us to capture objective biomarkers of responders and further understand who is most likely to respond to this regimen and, if successful,

2/

PridCor Therapeutics Advances SHIELD Study Through Dual Regulatory and Scientific Milestones With Peer-Reviewed Publication and FDA IND Exemption for Long COVID Program PridCor Therapeutics advances its SHIELD Long COVID study with a peer-reviewed publication and FDA confirmation of IND exemption....

Thanks to everyone for the interest in the work we are doing using combination antivirals #LongCOVID. As I mentioned, this first case series publication is a beginning, not an end - there is much more work to be done. To that end, we're pleased to

www.globenewswire.com/news-release...

1/

duration, high-dose approaches, not just a few days of a single drug. We didn’t have sufficient data to understand responder analysis in this case series but we will be launching a larger trial this year that will enable that. Here’s to starting off the year with some hope!
/end

combination antiviral and monoclonal therapies have a role in the treatment of #LongCOVID and other infection-associated chronic conditions and illnesses. But as @microbeminded2 and others showed us in their consensus statement it has to be long-

www.thelancet.com/journals/lan...

5/

period was long: 600 days. In the Val/Cel + Pax group, functional improvements were sustained across the 600 days of follow-up.

These are encouraging findings that I think more than justify the need for a larger clinical trial and validate the expert consensus that
4/

The people who chose the latter reported greater benefit. 2) The subset of people who started with Val/Cel only but then chose to retry the protocol with Paxlovid added experienced more benefit with the three drugs together than they did with the two drugs
3) The follow-up
3/

It is a small, open-label case series, but there are some interesting things that are worth noting that give me hope that what we are seeing is real and will hold up in a larger trial
1) People got to choose between Val/Cel only (called ‘IMC-2’ in the paper) and Val/Cel + Pax
2/

Great win early in the year to receive notification that our case series looking into Dr Pridgen’s Valacyclovir, Celecoxib and Paxlovid protocol seems to really help some folks with #LongCOVID. This paper is a start, not the be-all and end-all:

www.frontiersin.org/articles/10....

1/

that we are heading toward some meaningful and actionable answers in 2026. Let’s keep hope alive this year, but more importantly, let’s move with urgency to provide the answers that millions deserve.

/end

understanding is crucial to the development of general treatments that may help everyone a little vs. precision medicine targets that will help specific subtypes a lot. I’m grateful to the team of brilliant people I get to work with every day on these problems and hopeful
9/

the way that we test for pathogens and when we choose to treat them? These are fundamental questions that are crucial to our understanding of how various infection-associated chronic conditions and illnesses intersect and how they may differ completely. In turn, this
8/

3) What is the dynamic nature of pathogen persistence? If we used the best assays to test people for a variety pathogens every single day how would hormonal, immune and general physiological fluctuations alter their pathogen testing results? Should this fundamentally change
7/

antibody testing to understand this problem? I’m hoping that some of our antiviral/antibiotic (monotherapeutic and combination) trials that conclude in 2026, paired with our work with Francis Eun-Hyung Lee on her brilliant MENSA assay will help us to answer this question.
6/

reactivated pathogens mean? If your IgG titers for pathogens such as Babesia, Borrelia, EBV, CMV, etc are through the roof, what action should be taken? If you can knock these antibody numbers back to normal, will we see clinical improvement? Is it time to go beyond simple
5/

how SARS-CoV-2 is problematically persisting in people with #LongCOVID and how it is asymptomatically (for now) persisting in healthy controls. My hope is that @polybioRF’s VIPER program will be instrumental in shining light on this in 2026.

2) What does testing positive for
4/

clinical problems that we face.
1) Why do some people test positive on certain persistence assays and negative on others? How can we use all of the commercially and scientifically available assays to create a unifying test for persistence that helps us to understand when and
3/

hope we can answer this year. Since it isn’t my first time on the internet let me explicitly state: there are other questions that we will be chasing equally aggressively, but these are the ones that I most want to answer to up-level my own understanding of the scientific and
2/

Wishing everyone a happy new year and we will be forging ahead in 2026 with renewed energy to find answers for people living with #LongCOVID, #MECFS, chronic #lyme and other infection-associated chronic conditions and illnesses. Speaking for myself, here are some questions I
1/

helper given your long history of good works. You clearly have a lot of fans in the disabled community, so please apologize and commit to doing better.

Walt Whitman never said it, but Ted Lasso definitely did:
“Be curious, not judgmental”.

🙏🏻

/end

There are many clinicians, patients, advocates and scientists here in NY, a city hit harder than most by #COVID and #LongCOVID, who would happily sit down and talk with you about this topic. I truly hope you choose to learn from this and help, because I do believe you to be a
8/

You have a loud voice, a big following and your actions have consequences. I sincerely hope that you might open yourself up to being educated about all the reasons that those two maskers that you always see are brave and stalwart enough to be continuing to mask in public.
7/

done more than most in this space and it seems like you did it because you genuinely care for these folks. Given this, I hope I’m right that this moment on your @weeklyshowpodcast.bsky.social was a moment where you said something unkind because you are uninformed, not because you are cruel.
6/

sensible to adopt masking as on of the few reliable ways to protect oneself and others when entering and sharing public spaces. I want to give you the benefit of the doubt rather than condemn you outright given your history of meaningful advocacy for 9/11 survivors. You have
5/

just think that, until governments enact good-sense measures against the ongoing SARS-CoV-2 pandemic (I.e. air purifiers, better ventilation, routine testing, far UVC germicidal lights, development of post-exposure prophylaxis drugs and CURES for #LongCOVID), it is really
4/

body and drive immune dysregulation, hypercoagulation, oncogenic processes, nervous system dysfunction, cognitive decline and other terrible long-term effects. Furthermore, after hearing all the things that this virus drives, there are those of us who are perfectly healthy who
3/

worsening of their symptoms. There are countless millions more who are immunocompromised or love someone who is and must therefore mask to protect themselves from a virus that continues to spread without mitigation due to its novel ability amongst viruses to persist in the
2/